The world's leading journal on infectious diseases. Clinical ID, public health, microbiology, and everything in-between. Official publication of @IDSAinfo
CID extends another round of congratulations to our 2025 Reviewers of the Year! 🎉 First announced in Feb. 2026, the awardees are:
-Nicolás Cortés-Penfield, MD, FACP, FIDSA
-Esteban Martinez, MD, PhD
-Jose F. Portugal Gonzales, MD
Learn more: bit.ly/4aoKJ6S
Cefepime–Zidebactam for Infections Caused by Carbapenem-Resistant Gram-Negative Bacteria, Including Metallo-β-Lactamase Producers: A Phase 2, Open-Label, Single-Arm, Multicenter Study
✅ Just Accepted
⭐ Editor's Choice
🔗 bit.ly/47KCJKQ
On IDSA’s & @HIVMA’s Science Speaks blog: Check out insights from the editors of a new, ongoing series of articles in @CIDJournal highlighting how experienced clinicians deploy problem-solving skills to navigate complex cases. bit.ly/48mkxr0
Post-randomization exclusions and estimand clarity in a trial of direct long-acting cabotegravir/rilpivirine initiation
✅ Just Accepted
🔗 bit.ly/4eS3alx
Association Between Neighbourhood-level Antibiotic Utilization and the Rate of Community-Associated C. difficile (CA-CDI) Infection: An Ecological Study
✅ Just Accepted
🔗 bit.ly/4yI1fqX
Empirical Antifungal Treatment of Critically Ill Patients With Influenza-Associated Acute Respiratory Distress Syndrome: A Bayesian Perspective
✅ Just Accepted
bit.ly/4kcLjcx
Antibiotic Stewardship, Resistance, and Mortality in Vancomycin-Resistant Enterococcus: A Quasi-Experimental Study of Linezolid Restrictions
✅ Just Accepted
⭐ Editor's Choice
🔗 bit.ly/4BcHhqZ
The piperacillin-tazobactam is behaving like a prognostic factor, but that does not negate the pharmacodynamic hypothesis
✅ Just Accepted
🔗 bit.ly/3VXonUL